

REMARKS

Applicants first wish to thank Examiner Woitach for the very helpful telephone interview conducted on May 29, 2003, and they present in this reply the amendment discussed in that interview.

Claims 1-25, 27, 28, and 30-33 are pending. Claims 1-8, 10, and 12-19 have been withdrawn from consideration. Claims 1, 11, and 20-23 were rejected under 35 U.S.C. § 112, first paragraph, claims 11, 23, 27, 28, 32, and 33 were rejected under 35 U.S.C. § 112, second paragraph, and claims 24, 25, 30, and 31 were objected to for being dependent on rejected claims. Applicants address each of these rejections as follows.

Claim Amendments

As required by the Office, Applicants have canceled claims 1-8, 10, and 12-19, which are directed to a non-elected invention. For the record, Applicants reserve the right to pursue these claims in a continuing application. In addition, in view of the amendments to claims 9 and 11, Applicants cancel claims 22, 23, and 30-33.

Claims 9, 11, 20, and 21 have been amended to recite the stringent hybridization conditions described, for example, at page 34, lines 2-6, of the specification. The remaining claim amendments simply clarify the claim language. Support for the term "substantially pure" in claim 11 may be found, for example, at page 15, lines 2-3.

Rejection under 35 U.S.C. § 112, first paragraph

Claims 9, 11, and 20-23 were rejected under 35 U.S.C. § 112, first paragraph, for lack of written description in the specification. Claims 22 and 23 have been canceled and the rejection of these claims therefore is moot. Applicants address this rejection as applied to amended claims 9, 11, 20, and 21, as follows.

In response to Applicants' argument, presented in reply to the last Office Action, that the present claims fall within the fact pattern of Example 9 of the U.S. Patent & Trademark Office's Written Description Guidelines ("the Guidelines") the Office stated (page 5):

[T]he specific facts in the present disclosure are not directly comparable to those set forth in the hypothetical examples because related species would not be identified with the single disclosed SEQ ID NO:2.

In support of this statement the Office pointed to Blakely et al. (Nature 354:66-70, 1991; "Blakely") and Sze et al. (Nature 403:560-564, 2000; "Sze") as providing serotonin-gated anion channel sequences with "sufficient amino acid sequence differences wherein the polynucleotide sequences encoding the serotonin-gated anion channel would not be identified with SEQ ID NO:2." In this regard, Applicants note that neither Blakely nor Sze teach a serotonin-gated anion channel nucleic acid sequence. Blakely provides the sequence for a serotonin transporter and Sze provides the sequence of a tryptophan hydroxylase which is involved in serotonin biosynthesis. As these sequences do not encode serotonin-gated anion channels, one skilled in the art would not expect them to

hybridize to the complement of SEQ ID NO:2 under stringent conditions.

Moreover, the pending claims have been amended to recite the stringent hybridization conditions recited in canceled claims 22 and 23. The Office agreed that these hybridization conditions are stringent (see page 4), like those in Example 9. Thus, Applicants submit that the present claims, as amended, fall within the fact pattern set forth in Example 9 of the Guidelines.

Furthermore, the Office asserted that the current case is analogous to *Ex parte Maizel*, 27 U.S.P.Q.2d 1662 (Board of Appeals and Interferences, 1992). Applicants disagree. The claim under consideration in *Ex parte Maizel* recited the phrase "or a biologically functional equivalent thereof," but provided no structural limitations for this functional equivalent. In contrast, the present claims require that the nucleic acid sequence that encodes a serotonin-gated anion channel hybridizes under stringent conditions to the complement of the sequence of SEQ ID NO:2 and that the serotonin-gated anion channel selectively permits passage of anions into or out of a cell, or across a membrane, in response to serotonin. Thus, unlike the claim in *Ex parte Maizel*, the present claims include both functional and structural limitations, and the current case therefore is not analogous to the cited case.

In view of the arguments set forth above, Applicants submit that the written description rejection of amended claims 9, 11, 20, and 21, and their dependent claims should be withdrawn.

Rejection under 35 U.S.C. § 112, second paragraph

Claims 11 and 23, and their dependent claims, were rejected under 35 U.S.C. § 112, second paragraph, as being indefinite in their recitation of the phrase “purified serotonin-gated anion channel.” In particular, the Office stated (page 9):

The ability of measuring a current flux is dependent on generating a disequilibrium of ions on either side of the channel such as in the context of a cell, which can not be done with a purified protein.

Claim 23 has been canceled and the rejection of this claim therefore is moot. As amended, claim 11 now recites the phrase “substantially pure serotonin-gated anion channel.” Applicants define a “substantially pure polypeptide” at page 15, lines 2-3, of the specification as being “a polypeptide that has been separated from the components that naturally accompany it.” Thus, a substantially pure serotonin-gated anion channel may be expressed by a cell or be present in a membrane, and one skilled in the art would know how to measure current flux through such a channel. Applicants submit that the 35 U.S.C. § 112, second paragraph, rejection of claim 11 and its dependent claims should be withdrawn.


CONCLUSION

Applicants submit that the application is in condition for allowance and such action is hereby respectfully requested.

Enclosed is a Petition to extend the period for replying to the final Office Action for one month, to and including June 24, 2003. This Petition includes an authorization to charge the required fee to Deposit Account No. 03-2095. If there are any additional charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: June 9, 2003


Kristina Bicker-Brady, Ph.D.
Reg. No. 59,109

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045



21559

PATENT TRADEMARK OFFICE